Advertisement

Abstract

Ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone), an anaesthetic derivative of phencyclidine (PCP) with analgesic, neuroprotective and psychedelic properties, is an unusual anaesthetic in its ability to produce a “dissociative” state. It is the action (antagonism) at NMDA (N-methyl aspartate) receptors that is thought to underlie ketamine’s qualities. Whilst ketamine use in medicinal and veterinary settings is well documented and has a good safety record, the increase in its unregulated use outside of such controlled environments is a cause for concern. In non-medicinal use, the stereo-selective kinetics and the complex mechanism of action may lead to unpredictable effects. It is reported that the perceptual and mood changes observed in those who have consumed ketamine are highly sensitive to age, dose, route, previous experience and setting. At low doses stimulant effects predominate and environmental conditions are significant, but with higher doses psychedelic effects become the primary experience. When used recreationally in sub-therapeutic doses by inhalation (or insufflation) the alteration in perception of auditory, visual and painful stimuli result in a general “lack of responsive awareness” which puts the recreational user at risk of personal damage which can go unrecognized. The recreational use of this drug, the effects and potential risks associated with its unregulated use will be discussed.

Keywords

NMDA Receptor Episodic Memory Recreational User Ketamine Administration Anaesthetic Potency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gardner EL. Brain reward mechanisms. In: Lowinson H, Ruiz P, Millman RB, Langrod JG, editors. Substance abuse: a comprehensive textbook. 3rd ed. Baltimore: Williams and Wilkins; 1996. p. 51–85.Google Scholar
  2. 2.
    Bishop RA, Litch JA, Stanton JM. Ketamine anesthesia at high altitude. High Alt Med Biol. 2000;1(2):111–4.PubMedGoogle Scholar
  3. 3.
    Cottingham R, Thomson K. Use of ketamine in prolonged entrapment. J Accid Emerg Med. 1994;11(3):189–91.PubMedGoogle Scholar
  4. 4.
    White PF, Way WL, Trevor AJ. Ketamine: its pharmacology and therapeutic uses. Anaesthesiology. 1982;56:1.Google Scholar
  5. 5.
    Bush M, Grobler DG, Raath JP, Phillips Jr LG, Stamper MA, Lance WR. Use of medetomidine and ketamine for immobilization of free-ranging giraffes. J Am Vet Med Assoc. 2001;218(2):245–9.PubMedGoogle Scholar
  6. 6.
    Vercruysse Jr J, Mortelmans J. The chemical restraint of apes and monkeys by means of phencyclidine or ketamine. Acta Zool Pathol Antverpiensia. 1978;70:211–20.Google Scholar
  7. 7.
    Hetem LA, Danion JM, Diemunsch P, Brandt C. Effect of a ­subanesthetic dose of ketamine on memory and conscious ­awareness in healthy volunteers. Psychopharmacology. 2001;22:59–72.Google Scholar
  8. 8.
    Giannini AJ. Drugs of abuse. 2nd ed. Los Angeles: Practice Management Information Company; 1997. ISBN 1-57066-053-0.Google Scholar
  9. 9.
    Newcomber JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW. Ketamine induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106–18.Google Scholar
  10. 10.
    Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS. Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199–214.PubMedGoogle Scholar
  11. 11.
    Abi-Saab WM, D’Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry. 1998;31:104–9.PubMedGoogle Scholar
  12. 12.
    Carpenter WT. The schizophrenia ketamine challenge study debate. Biol Psychiatry. 1999;46(8):1081–91.PubMedGoogle Scholar
  13. 13.
    Morgan CAJ, Curran HJ. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology. 2006;188:408–24.PubMedGoogle Scholar
  14. 14.
    Fletcher PC, Honey GD. Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends Cogn Sci. 2006;10:167–74.PubMedGoogle Scholar
  15. 15.
    Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–30.PubMedGoogle Scholar
  16. 16.
    Malhotra AK, Pinals DA, Caleb MA, Elman I, Clifton A, Pickar D, Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 1997;17:141–50.PubMedGoogle Scholar
  17. 17.
    Olney J, Labruyere J, Wang G, Wozniak D, Price MT, Sesma M. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515–8.PubMedGoogle Scholar
  18. 18.
    Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology. 2003;169:404–11.PubMedGoogle Scholar
  19. 19.
    Tamlyn D, McKenna PJ, Mortimer AM, Lund CE, Hammond S, Baddeley AD. Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character. Psychol Med. 1992;22:101–15.PubMedGoogle Scholar
  20. 20.
    Saykin AJ, Gur RC, Gur RE, Mozeley PD, Mozeley LH, Resnick SM, Kester DB, Stafiniak P. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48:618–24.PubMedGoogle Scholar
  21. 21.
    Keilhoff G, Bernstein HG, Becker A, Grecksch G, Wolf G. Increased neurogenesis in a rat ketamine model of schizophrenia. Biol Psychiatry. 2004;56:317–22.PubMedGoogle Scholar
  22. 22.
    Feldman RS, Meyer JS, Quenzer LF. Principles of neuropsychopharmacology. Sunderland, MA: Sinauer; 1997.Google Scholar
  23. 23.
    Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Rev. 2000;31:288–94.PubMedGoogle Scholar
  24. 24.
    Rothman SM, Thurston JB, Hauhart RE, Clark GD, Soloman JS. Ketamine protects hippocampal neurons from anoxia in vitro. Neuroscience. 1987;21:673–8.PubMedGoogle Scholar
  25. 25.
    Meldrum B. Possible therapeutic applications for antagonists of excitatory amino acid neurotransmitters. Clin Sci. 1985;68:113–22.PubMedGoogle Scholar
  26. 26.
    Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 1989;243(4889):398–400.PubMedGoogle Scholar
  27. 27.
    Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry. 1998;55(4):354–60.PubMedGoogle Scholar
  28. 28.
    Trujillo KA. The effects of non-competitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology. 1995;13(4):301–7.PubMedGoogle Scholar
  29. 29.
    Byrd LD, Standish LJ, Howell LL. Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs. Eur J Pharmacol. 1987;144(3):331–41.PubMedGoogle Scholar
  30. 30.
    Kissin I, Bright CA, Bradley Jr EL. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anaesth Analg. 2000;91(6):1483–8.Google Scholar
  31. 31.
    Lahti AC, Warfel D, Michaelidis T, Weiler MA, Frey K, Tamminga CA. Long-term outcome of patients who receive ketamine during research. Biol Psychiatry. 2001;49:869–75.PubMedGoogle Scholar
  32. 32.
    Hersack RA. Ketamine’s psychological effects do not contraindicate its use based on a patient’s occupation. Aviat Space Environ Med. 1994;65:1041–6.PubMedGoogle Scholar
  33. 33.
    Ishihara H, Kudo H, Murakawa T, Kudo A, Takahashi S, Matsuki A. Uneventful total intravenous anaesthesia with ketamine for schizophrenic surgical patients. Eur J Anaesthesiol. 1997;14:47–51.PubMedGoogle Scholar
  34. 34.
    Carpenter WT. The schizophrenia ketamine challenge study debate. Biol Psychiatry. 1999;46:1081–91.PubMedGoogle Scholar
  35. 35.
    Lahti AC, Warfel D, Michaelidis T, Weiler MA, Frey K, Tamminga CA. Outcome of patients who receive ketamine. Biol Psychiatry. 2001;49:869–75.PubMedGoogle Scholar
  36. 36.
    Gboniem MM, Hinricks JV, Mewaldt SP, Peterson RC. Ketamine: behavioural effects of subanaesthetic doses. J Clin Psychopharmacol. 1985;5:70–7.Google Scholar
  37. 37.
    Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 2003;69:23–8.PubMedGoogle Scholar
  38. 38.
    Dotson JW, Ackerman DL, West LJ. Ketamine abuse. J Drug Issues. 1995;25:751–7.Google Scholar
  39. 39.
    Zinberg NE. The basis for controlled intoxicant use. New Haven: Yale University Press; 1984.Google Scholar
  40. 40.
    Jansen KL. Non medical use of ketamine. BMJ. 1993;306(6878):601–2.PubMedGoogle Scholar
  41. 41.
    Jansen KLR. Ketamine: dreams and realities. Santa Cruz: Multi disciplinary Association for Psychedelic Studies; 2000.Google Scholar
  42. 42.
    Release. Release drugs and dance survey: an insight into the ­culture. London: Release; 1997 (Contact: Release, 388 Old Street, London EC1V 9LT, UK).Google Scholar
  43. 43.
    Skovmand K. Swedes alarmed at ketamine misuse. Lancet. 1996;348(9020):122.Google Scholar
  44. 44.
    White JM, Ryan CF. Pharmacological properties of ketamine. Drug Alcohol Rev. 1996;15(2):145–55.PubMedGoogle Scholar
  45. 45.
    Shapiro H. Ketamine fact sheet. London: Institute for the Study of Drug Dependence (ISDD); 1991.Google Scholar
  46. 46.
    Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend. 2001;64(1):9–17.PubMedGoogle Scholar
  47. 47.
    Mixmag. The Mixmag drug survey 2004: the world’s biggest drug survey. London: Emap; 2004. p. 30–51.Google Scholar
  48. 48.
    Topp L, Hando J, Degenhardt L, Dillon P, Roche A, Solowiji N. Ecstasy use in Australia, Monograph Number 39. Sydney: National Drug and Alcohol Research Centre; 1998.Google Scholar
  49. 49.
    Topp L, Breen C, Kaye S, Darke S, NSW Party Drug Trends. Findings from the Illicit Drug Reporting System (IDRS), Technical Report Number 136. Sydney: National Drug and Alcohol Research Centre; 2001.Google Scholar
  50. 50.
    McCambridge J, Winstock A, Hunt N, Mitcheson L. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res. 2007;13(1):57–64.PubMedGoogle Scholar
  51. 51.
    Murphy R, Roe S. Drug misuse declared: findings from the 2006/2007 British Crime Survey. 2007. ISBN: 978-1-84726-541-8. http://www.homeoffice.gov.uk/rds/pdfs07/hosb1807.pdf.
  52. 52.
    Drug Enforcement Agency, Ketamine abuse increasing, February 4, 1997.Google Scholar
  53. 53.
    Gough N. Ketamine: China’s other white powder. Time Asia.com. 2003. http://www.time.com/time/asia/covers/1101020520/ketamine.html.
  54. 54.
    Hansen G, Jenson SB, Chandresh L, Hilden T. The psychotropic effect of ketamine. J Psychoactive Drugs. 1988;20(4):419–25.PubMedGoogle Scholar
  55. 55.
    Jansen KL. A review of the nonmedical use of ketamine: use, users and consequences. Psychoactive Drugs. 2000;32(4):419–33.Google Scholar
  56. 56.
    Tori SP. Ketamine abuse “Special K”. Pennsylvania: Middle Atlantic-Great Lakes Organized Crime Law Enforcement Network (MAGLO-CLEN); 1996.Google Scholar
  57. 57.
    Winstock AR, Wolff K, Ramsey J. Ecstasy pill testing: harm minimisation gone too far? Addiction. 2001;96(8):1139–48.PubMedGoogle Scholar
  58. 58.
    Bohr N. On atoms and human knowledge. Daedalus. 1958;87(2):53–61.Google Scholar
  59. 59.
    Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJA, Curran HV. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95:219–29.PubMedGoogle Scholar
  60. 60.
    http://en.wikipedia.org/wiki/Ketamine. Wikipedia, the free encyclopedia. Accessed 23 April 2009.
  61. 61.
    Dalgarno PJ, Shewan D. Illicit use of ketamine in Scotland. J Psychoactive Drugs. 1996;28(2):191–9.PubMedGoogle Scholar
  62. 62.
    Huang GS, Yeh CC, Kong SS, Lin TC, Ho ST. Wong Intra-articular ketamine for pain control following arthroscopic knee surgery. Acta Anaesthesiol. 2000;152(3):283–8.Google Scholar
  63. 63.
    Azevedo VM, Lauretti GR, Pereira NL, Reiss MP. Transdermal ketamine as an adjuvant for post operative analgesia after abdominal gynecological surgery using lidocaine epidural blockade. Anesth Analg. 2000;91(6):1479–82.PubMedGoogle Scholar
  64. 64.
    Marhofer P, Freitag H, Hochtl A, Greher M, Erlacher W, Semsroth M. S(+)-Ketamine for rectal premedication in children. Anesth Analg. 2001;92(1):62–5.PubMedGoogle Scholar
  65. 65.
    Siegel RK. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Peterson RC, Stillman RC, editors. Phencyclidine abuse: an appraisal. Rockville: National Institute on Drug Abuse; 1978.Google Scholar
  66. 66.
    Kienbaum P, Heuter T, Pavlakovic G, Michel MC, Peters J. S(+)-ketamine increases muscle sympathetic activity and maintains the neural response to hypotensive challenges in humans. Anesthesiology. 2001;94(2):252–8.PubMedGoogle Scholar
  67. 67.
    Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and ­analgesic effects of MI and oral ketamine. Br J Anaesth. 1981;53:805–10.PubMedGoogle Scholar
  68. 68.
    Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anesth. 1989;36(2):186–97.PubMedGoogle Scholar
  69. 69.
    Weiner AL, Vieria L, McKay CA, Bayer MJ. Ketamine abusers presenting to the Emergency Department: a case series. J Emerg Med. 2000;18(4):447–51.PubMedGoogle Scholar
  70. 70.
    Doenicke A, Kugler J, Mayer M, Angster R, Hoffman P. Influence of racemic ketamine and S-(+) – ketamine on vigilance, performance and wellbeing. Anaesthestist. 1992;41:610–8.Google Scholar
  71. 71.
    Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory ­perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992;260(3):1209–13.PubMedGoogle Scholar
  72. 72.
    Zeilhofer HU, Swandulla D, Geisslinger G, Brune K. Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol. 1992;213:155–8.PubMedGoogle Scholar
  73. 73.
    Engelhardt W. Recovery and psychic emergence reactions after S-(+)-ketamine. Anaesthesist. 1997(Suppl 1);46:538–42.Google Scholar
  74. 74.
    Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilization produced by (s)- and (R) – ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7:25–38.PubMedGoogle Scholar
  75. 75.
    Øye I, Hustveit O, Maurset A, Ratti Moberg E, Paulsen O, Skoglund LA. Thc chiral forms of ketamine as probes for NMDA-receptor function in humans. In: Kameyama T, Nabeshima T, Domino EF, editors. NMDA receptor related agents: biochemistry, pharmacology and behavior. Ann Arbor: NPP Books; 1991. p. 381–9.Google Scholar
  76. 76.
    Fagg GE. Phencyclidine and related drugs bind to the activated NMDA receptor channel complex in rat brain membranes. Neurosci Lett. 1987;76:221–9.PubMedGoogle Scholar
  77. 77.
    Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurons by N-methyl-D-Aspartate. Br J Pharmacol. 1983;79:565–75.PubMedGoogle Scholar
  78. 78.
    Morris RGM, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist. AP5. Nature. 1986;319:774–6.PubMedGoogle Scholar
  79. 79.
    Lynch G, Baudry M. The biochemistry of memory: a new and specific hypothesis. Science. 1984;224:1057–63.PubMedGoogle Scholar
  80. 80.
    Cotman CW, Monaghan DT. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci. 1988;11:60–80.Google Scholar
  81. 81.
    Chambers RA, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry. 1999;4(4):274–81.PubMedGoogle Scholar
  82. 82.
    Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D- aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57(3):270–6.PubMedGoogle Scholar
  83. 83.
    Moghaddam B, Adams B, Verma A, Daly A. Activation of ­glutaminergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to doperminergic and cognitive disruptions associations with the prefrontal cortex. J Neurosci. 1997;17:2921–7.PubMedGoogle Scholar
  84. 84.
    Stone JM, Erlandsson K, Arstad E, Bressan RA, Squassante L, Teneggi V, Ell PJ, Pilowsky LS. Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo. Nucl Med Biol. 2006;33:239–43.PubMedGoogle Scholar
  85. 85.
    Wolff K, Winstock. Ketamine: from medicine to misuse. Rev CNS Drugs. 2006;20:199–218.Google Scholar
  86. 86.
    Dillon P, Copeland J, Jansen K. Patterns of use and harms ­associated with non-medical ketamine use. Drug Alcohol Depend. 2003;69:23–8.PubMedGoogle Scholar
  87. 87.
    Leary T, Sirius RU. Design for dying. London: Thorsons/Harper Collins; 1997.Google Scholar
  88. 88.
    Adams HA, Thiel A, Jung A, Fengler G, Hempelman G. Effects of S-(=)-ketamine on the endocrine and cardiovascular parameters. Recovery and psychomimetic reactions in volunteers. Anaesthesist. 1992;41:558–96.Google Scholar
  89. 89.
    Jevtovic-Todorovic V, Todorovic SM, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumsk CF, Olney JW. Nitrous Oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4:460–3.PubMedGoogle Scholar
  90. 90.
    Grinspoon L, Bakalar JB. The major psychedelic drugs: sources and effects. Chap 2. New York: Basic Books; 1981. p. 32–6.Google Scholar
  91. 91.
    Giannini AJ, Loiselle RH, Giannini MC, Price WA. Phencyclidine and the dissociatives. Med Psychiatry. 1987;3(3):197–204.Google Scholar
  92. 92.
    Stafford P. Contrasting profiles. In: Stafford P, editor. Psychedelics encyclopedia. 3rd ed. Berkeley, CA: Ronin; 1991. p. 392–5.Google Scholar
  93. 93.
    Gill JR, Stajic M. Ketamine in non-hospital and hospital deaths in New York City. J Forensic Sci. 2000;45(3):655–8.PubMedGoogle Scholar
  94. 94.
    Baer G, Parkas P. Ketamine-induced psychopathological changes in normal volunteers during conditions used for experimental psychoses (author’s transl). Anaesthesist. 1981;30(5):251–6.PubMedGoogle Scholar
  95. 95.
    Johnston REA. Ketamine trip. Anaesthesiology. 1973;39:460–1 (Clinical workshop, Letter to Editor).Google Scholar
  96. 96.
    Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. NMDA receptor function and human ­cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996;16:120–25.Google Scholar
  97. 97.
    Green SM, Johnson NE. Ketamine sedation for pediatric procedures: part 2, review and implications. Ann Emerg Med. 1990;19:1033–46.PubMedGoogle Scholar
  98. 98.
    Ghonheim MM, Hinrichs JV, Mewaldt SP, Peterson RC. Ketamine: behavioural effects of subanaesthetic doses. J Clin Psychopharmacol. 1985;5:70–7.Google Scholar
  99. 99.
    Merle R. “Special-K” is latest US drug fad. The Seattle Times, 1997, June 20.Google Scholar
  100. 100.
    Hansen G, Jenson SB, Chandresh L, Hilden T. The psychotropic effect of ketamine. J Psychoactive Drugs. 1988;20(4):419–25.PubMedGoogle Scholar
  101. 101.
    Wolff K, Hay AWM, Sherlock K, Conner M. Contents of Ecstasy. Lancet. 1996;346:1100–1.Google Scholar
  102. 102.
    Ahmed SN, Petchkovsky L. Abuse of ketamine. Br J Psychiatry. 1980;137:303.PubMedGoogle Scholar
  103. 103.
    Curran HV, Morgan C. Cognitive dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction. 2000;95(4):575–90.PubMedGoogle Scholar
  104. 104.
    Curran HV, Monaghan L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction. 2001;96(5):749–60.PubMedGoogle Scholar
  105. 105.
    Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkuns SA, Simkovitz P, Hurley A, Cooper T, Volkow ND, Cancro R. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11-raclopride in normal human subjects. Neuropsychopharmacology. 1998;18:18–25.PubMedGoogle Scholar
  106. 106.
    Klein M, Calderon S, Hayes B. Abuse liability assessment of neuro-protectants. Ann NY Acad Sci. 1999;890:515–2.PubMedGoogle Scholar
  107. 107.
    Beardsley PM, Balster RL. Behavioral dependence upon phencyclidine and ketamine in the rat. J Pharmacol Exp Ther. 1987;242(1):203–112.PubMedGoogle Scholar
  108. 108.
    Jansen KL. Ketamine–can chronic use impair memory? Int J Addict. 1990;25(2):133–9.PubMedGoogle Scholar
  109. 109.
    Kamaya H, Krishna PR. Ketamine addiction. Anesthesiology. 1987;67(5):861–2.PubMedGoogle Scholar
  110. 110.
    Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994;151(5):779.PubMedGoogle Scholar
  111. 111.
    Moore NN, Bostwick JM. Ketamine dependence in anesthesia providers. Psychosomatics. 1999;40(4):356–9.PubMedGoogle Scholar
  112. 112.
    Steen PA, Michenfelder JD. Neurotoxicity of anesthetics. Anesthesiology. 1997;50:437.Google Scholar
  113. 113.
    Schorn TOF, Whitwam JG. Are there long term effects of ketamine on the central nervous system? Br J Anaesth. 1980;52:967–8.PubMedGoogle Scholar
  114. 114.
    Siegal RK. Phenocyclidine and ketamine intoxication a study of 4 populations of recreational users. Natl Inst Drug Abuse Res Monogr Ser. 1978;21:110–9.Google Scholar
  115. 115.
    Lilly JC. The scientist: a novel autobiography. New York: J.B. Lippincott; 1978.Google Scholar
  116. 116.
    Adler CM, Goldbert TE, Malhotra AU, Pickar D, Breir A. Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. Biol Psychiatry. 1998;43:811–6.PubMedGoogle Scholar
  117. 117.
    Albin M, Dresner J, Paolin A, Sweet R, Virtue R, Miller G. Long-term personality evaluation in patients subjected to ketamine hydrochloride and other anaesthetic agents. Pharmacology: Abstracts of Scientific Papers. American Society of Anesthesiologists Annual Meeting, 1970. p. 166.Google Scholar
  118. 118.
    Cottrell AM, Athreeres R, Weinstock P, Warren K, Gillatt D. An emerging problem: urinary tract disease associated with chronic ketamine use. BMJ. 2008;336(7651):973. doi: 10.1136/bmj.39562.711713.80.Google Scholar
  119. 119.
    Colebunders B, Van Erps P. Cystitis due to the use of ketamine as a recreational drug: a case report. J Med Case Rep. 2008;2:219. doi: 10.1186/1752-1947-2-219.PubMedGoogle Scholar
  120. 120.
    Ng SH, Tse ML, Ng HW, Lau FL. Emergency department presentation of ketamine abusers in Honmg Kong: a review of 233 cases. Hong Kong Med J. 2010;16:6–11.PubMedGoogle Scholar
  121. 121.
    Lily JC. The scientist: a novel autobiography. New York: J.B Lippincott; 1978.Google Scholar
  122. 122.
    Melkonian DL, Meschcheriakov AV. Possibility of predicting and preventing psychotic disorders during ketamine anesthesia. Anesteziol Reanimatol. 1989;3:15–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Addiction Science, Institute of PsychiatryKing’s College LondonLondonUK

Personalised recommendations